Advances in HPV-associated tumor management: Therapeutic strategies and emerging insights

With the rapid increase in the incidence of cervical cancer, anal cancer and other cancers, human papillomavirus (HPV) infection has become a growing concern. Persistent infection with high-risk HPV is a major cause of malignant tumors. In addition, microbiota and viruses such as human immunodeficiency virus, herpes simplex virus, and Epstein-Barr virus are closely associated with HPV infection. The limited effectiveness of existing treatments for HPV-associated tumors and the high rates of recurrence and metastasis in patients create an urgent need for novel and effective approaches. In recent years, HPV vaccine coverage has increased and can reduce the incidence of serious adverse events. Overall, this article provides a comprehensive overview of HPV biology, microbiome, and other viral interactions in cancer development, highlighting the need for a more comprehensive approach to cancer prevention and treatment. Current and emerging HPV-related cancer control and treatment strategies are also further explored.

Automated summary

With the increasing incidence of cervical cancer, anal cancer, and other cancers, the concern over human papillomavirus (HPV) infection has grown. Persistent infection with high-risk HPV is a major cause of malignant tumors. Moreover, HPV infection is closely associated with microbiota and viruses such as human immunodeficiency virus, herpes simplex virus, and Epstein-Barr virus. The limited effectiveness of current treatments for HPV-associated tumors and the high rates of recurrence and metastasis create the need for innovative approaches. The article provides a comprehensive overview of HPV biology, microbiome, viral interactions, and highlights the importance of a more holistic approach to cancer prevention and treatment. Current and emerging strategies for HPV-related cancer control and treatment are also explored.